SCHEMBL10098352

SCHEMBL10098352

COCCOc1ccnc(C(=O)O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.47
KDM6B O15054 1/20 0.47
TET3 O43151 1/20 0.47
KDM4A O75164 1/20 0.47
BBOX1 O75936 1/20 0.47
MAPT P10636 1/20 0.47
KDM5A P29375 1/20 0.47
KDM5C P41229 1/20 0.47
ASPH Q12797 1/20 0.47
KDM4D Q6B0I6 1/20 0.47
TET2 Q6N021 1/20 0.47
ALKBH5 Q6P6C2 1/20 0.47
KDM7A Q6ZMT4 1/20 0.47
KDM8 Q8N371 1/20 0.47
TET1 Q8NFU7 1/20 0.47
EGLN2 Q96KS0 1/20 0.47
FTO Q9C0B1 1/20 0.47
EGLN1 Q9GZT9 1/20 0.47
KDM4C Q9H3R0 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22589659 0.87 MAP3K5 (0.41) ALDH1A1MAPTSLC22A12MAP3K5LNPEP
SCHEMBL4134527 0.84 KDM4E (0.45) KDM4EALDH1A1KDM6BTET3KDM4A
SCHEMBL726595 0.84 RECQL (0.47) ALDH1A1MAPTSLC22A12MAP3K5LNPEP
SCHEMBL2455403 0.84 TP53 (0.51) KDM4EALDH1A1KDM6BTET3KDM4A
SCHEMBL27639521 0.81 KDM4E (0.52) KDM4EALDH1A1KDM6BTET3KDM4A
SCHEMBL10986249 0.81 PLA2G2A (0.56) LNPEP
SCHEMBL1023538 0.81 ALDH1A1 (0.55) KDM4EALDH1A1KDM6BTET3KDM4A
SCHEMBL29455922 0.81 ALDH1A1 (0.55) KDM4EALDH1A1KDM6BTET3KDM4A
SCHEMBL4069028 0.80 ALPL (0.46) MAPTMAOA
SCHEMBL28957013 0.80 ALDH1A1 (0.53) KDM4EALDH1A1KDM6BTET3KDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962830-B2 Protein kinase inhibitors and methods of treatment THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2015-02-24 US disclosed
US-8962830-B2 Protein kinase inhibitors and methods of treatment THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2015-02-24 US disclosed
US-20130184274-A1 Protein Kinase Inhibitors and Methods of Treatment THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2013-07-18 US disclosed
US-20130184274-A1 Protein Kinase Inhibitors and Methods of Treatment THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2013-07-18 US disclosed
WO-2012003544-A1 PROTEIN KINASE INHIBITORS AND METHODS OF TREATMENT THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184274-A1 Protein Kinase Inhibitors and Methods of Treatment PRKDC, PRKACA, PRKX KDM4E 904/4885ALDH1A1 2878/4885KDM6B 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.